'No Surprise' Says Vertex As NICE Fails To Recommend Orkambi In CF
This article was originally published in Scrip
Executive Summary
Vertex Pharmaceuticals Inc. says it is "not surprised" that NICE has issued draft guidance not recommending Orkambi (lumacaftor/ivacaftor) for use on the NHS in England.